仔猪缺氧缺血性脑病模型中出生后阿奇霉素的神经保护与抗炎作用
在炎症放大的缺氧缺血仔猪模型中,静脉阿奇霉素安全,并与改善振幅整合脑电图背景、增加神经元存活及小胶质细胞免疫调节相关;对磁共振波谱乳酸/N-乙酰天冬氨酸峰面积比获益有限。
要点
- 阿奇霉素在炎症放大缺氧缺血后给药安全,并改善脑电图背景。
- 阿奇霉素与神经元存活增加和小胶质细胞免疫调节相关。
- 对乳酸/N-乙酰天冬氨酸峰面积比的获益有限。
核心结论
- 在炎症放大的缺氧缺血仔猪模型中,出生后静脉阿奇霉素安全,并与神经元存活增加、小胶质细胞免疫调节、振幅整合脑电图恢复改善及乳酸/N-乙酰天冬氨酸峰面积比适度获益相关。
研究设计与样本
- 二十五只新生仔猪在炎症放大缺氧缺血后1小时随机接受溶媒(n=12)或阿奇霉素20 mg/kg(n=13),并在24和48小时重复给药。
主要发现
- 阿奇霉素组振幅整合脑电图背景改善的优效概率为98.6%。
- 阿奇霉素组神经元核抗原(NeuN+)细胞总体增加的优效概率为97.8%。
- 阿奇霉素组Iba1+细胞增加的优效概率为99.6%,Iba1分支指数增加的优效概率为99.6%。
- 磁共振波谱乳酸/N-乙酰天冬氨酸峰面积比获益在丘脑和白质体素中的优效概率分别为82.7%和68.5%。
关键数值与推荐
- 贝叶斯分析采用无信息先验,预设优效概率阈值(Pr[sup])为95%。
- 血浆阿奇霉素峰浓度(Cmax)约为2 mg/mL,脑组织浓度约为1.5 mg/kg。
临床怎么用
- 在无法获益于治疗性低温的低中收入国家,阿奇霉素单药可能为缺氧缺血性脑病提供改善结局的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an urgent need for cytoprotective therapies for hypoxic-ischemic encephalopathy in low- and middle-income countries, where therapeutic hypothermia is not beneficial. Infection and inflammation are important risk factors for hypoxic-ischemic encephalopathy in sub-Saharan Africa, and immunomodulatory therapies might improve outcomes. Azithromycin is neuroprotective in rodent hypoxic-ischemic encephalopathy models but validation in large animal models is needed. Our aim was to assess safety and efficacy of intravenous azithromycin after inflammation-amplified hypoxia-ischemia in newborn piglets. METHODS: Twenty-five piglets underwent inflammation-amplified hypoxia-ischemia by bilateral carotid artery occlusion and reduction in FiO2 to 6% at 4 hours after the start of Escherichia coli liposaccharide infusion (2 mcg/kg bolus+1 mcg/kg per hour over 12 hours). At 1 hour after inflammation-amplified hypoxia-ischemia, piglets were randomized to receive vehicle (n=12) or azithromycin 20 mg/kg over 1 hour (n=13), repeated at 24 and 48 hours. Piglets underwent neurocritical care for 65 hours, including continuous amplitude-integrated encephalography, magnetic resonance imaging/magnetic resonance spectroscopy at 60 hours, and brain immunohistochemistry. Group differences were evaluated by Bayesian analysis with noninformative priors; the a priori threshold probability of superiority (Pr[sup]) was set at 95%. RESULTS: Insult severity did not differ between groups. Plasma azithromycin peak concentration (Cmax) of ≈2 mg/mL and brain tissue concentrations of ≈1.5 mg/kg were achieved. Azithromycin was associated with improved amplitude-integrated encephalography background (Pr[sup]=98.6%), an overall increase in neuronal nuclear antigen (NeuN+) cells (Pr[sup]=97.8%), increase in Iba1 (ionized calcium-binding adapter molecule 1)+cells (Pr[sup]=99.6%) and increase in Iba1 ramification index (resting microglial morphology; Pr[sup]=99.6%). The treatment benefit on magnetic resonance spectroscopy lactate to N-acetyl aspartate peak area ratio was modest (Pr[sup] of 82.7% and 68.5% in the thalamic and white matter voxels, respectively). CONCLUSIONS: Azithromycin, administered after inflammation-amplified hypoxia-ischemia was safe and associated with increased neuronal survival, microglial immunomodulation, enhanced amplitude-integrated encephalography recovery, and a modest benefit on lactate to N-acetyl aspartate peak area ratio. These safety and efficacy data of azithromycin as a monotherapy hold promise to improve outcomes for hypoxic-ischemic encephalopathy in low- and middle-income countries.
引用
- Pang R, Meehan C, Maple G, et al. Postnatal Azithromycin Is Neuroprotective and Anti-Inflammatory in a Piglet Model of Hypoxic-Ischemic Encephalopathy. Stroke. 2026. PMID: 41685447. doi:10.1161/STROKEAHA.125.054318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。